Cargando…
Preclinical evaluation of an (111)In/(225)Ac theranostic targeting transformed MUC1 for triple negative breast cancer
Rationale: Transformed MUC1 (tMUC1) is a cancer-associated antigen that is overexpressed in >90% of triple-negative breast cancers (TNBC), a highly metastatic and aggressive subtype of breast cancer. TAB004, a murine antibody targeting tMUC1, has shown efficacy for the targeted delivery of therap...
Autores principales: | Kelly, Vanessa J, Wu, Shu-Ta, Gottumukkala, Vijay, Coelho, Richard, Palmer, Keryn, Nair, Surabhi, Erick, Timothy, Puri, Rahul, Ilovich, Ohad, Mukherjee, Pinku |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7295045/ https://www.ncbi.nlm.nih.gov/pubmed/32550914 http://dx.doi.org/10.7150/thno.38236 |
Ejemplares similares
-
[(225)Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer: Preclinical Evaluation and Comparison with [(225)Ac]Ac-PSMA-617
por: Busslinger, Sarah D., et al.
Publicado: (2022) -
Cure of Disseminated Human Lymphoma with [(225)Ac]Ac-Ofatumumab in a Preclinical Model
por: Longtine, Mark S., et al.
Publicado: (2023) -
Initial Findings on the Use of [(225)Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumors
por: Demirci, Emre, et al.
Publicado: (2023) -
[(225)Ac]Ac- and [(111)In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts
por: Kondo, Misaki, et al.
Publicado: (2023) -
Evaluation of (134)Ce/(134)La as a PET Imaging Theranostic Pair for (225)Ac α-Radiotherapeutics
por: Bobba, Kondapa Naidu, et al.
Publicado: (2023)